9
Oct
2015

Vertex Takes Heat, Valeant Takes Even More, and Express Scripts Cuts a Deal

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

RevMed’s Moment in the Sun, In Vivo CAR-Ts Shine & NewLimit’s Healthspan Haul
Vaccines Get a Boost, Apogee Hunts Down Dupixent, GSK Raises the Bar in HepB
Lilly’s Triple-G Delivers, Parabilis Eyes IPO, & Regeneron’s LAG-3 Whiff
FDA Boss Pushed Out, BMS Bets on China & Isomorphic’s Megaround